Cancer Research

MRI of the brain showing glioblastoma
#Brain cancer #Cancer vaccine #MimiVax #Oncology #Phase II trial

Cancer vaccine extends survival in glioblastoma trial

MimiVax and Roswell Park Comprehensive Cancer Center have announced results from the SURVIVE Phase IIb clinical trial evaluating novel cancer vaccine, SurVaxM, in patients with newly diagnosed glioblastoma.  The data reflect the first reportable results from the fully enrolled clinical trial, which has been underway since 2022… Read More

#Cancer Research #News

Cancer cells
#Cancer Research UK #Collaboration #Oncology #ORIC Pharmaceuticals

Cancer Research UK and ORIC partner on CIP2A-targeted therapy

Cancer Research UK has signed an agreement with ORIC Pharmaceuticals to advance ORIC-259, a potential first-in-class CIP2A-targeted therapy, into clinical development.  Under the agreement, Cancer Research UK’s Centre for Drug Development (CDD) will fully fund, sponsor, design and execute a Phase I/II clinical trial of ORIC-259, including… Read More

#Cancer Research #News

CAR-T cells attack cancer cells
#CAR-T #Cell therapy #Generate Biomedicines #Oncology #Ovarian cancer

First human trials in ovarian cancer for ‘armoured’ CAR-T therapy

Roswell Park Comprehensive Cancer Center and Generate Biomedicines have dosed the first patient in a first-in-human clinical trial evaluating GB-5267, an autologous IL‑18–armoured CAR T-cell therapy.  The therapy is designed to overcome key barriers that have limited the success of cellular therapies in solid tumours.  … Read More

#Cancer Research #News #Trending News

KRAS
#Award #KRAS #Oncology #Pancreatic cancer #Revolution Medicines

$1 million Stephenson Global Prize honours pioneering KRAS research

Kevan Shokat has been named the 2026 Stephenson Global Prize Laureate, receiving $1 million for his pioneering contributions to pancreatic cancer research.   His discoveries helped transform decades of scientific thinking about KRAS, one of cancer’s most important and historically difficult-to-target drivers, and usher in a new generation… Read More

#Cancer Research #News #Trending News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Ona Therapeutics #Oncology #Phase I trial

Ona Therapeutics moves to Phase I with ADC for advanced cancers

Ona Therapeutics has progressed to a Phase Ia clinical development of its lead first-in-class antibody-drug conjugate (ADC), ONA-255, for the treatment of advanced cancers.   The company says that more than half of the patients planned for the study have already been enrolled, with the trial continuing to… Read More

#Cancer Research #News

Lung cancer
#Johnson & Johnson #Lung cancer #Non-small cell lung cancer (NSCLC) #Oncology #Phase III trial

Amivantamab shown to extend survival in advanced NSCLC

Johnson & Johnson has announced final overall survival (OS) results from the Phase III PAPILLON study of first-line intravenous (IV) Rybrevant (amivantamab).  The fully-human EGFR-MET bispecific antibody was assessed with carboplatin-pemetrexed chemotherapy, versus chemotherapy alone, in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth… Read More

#Cancer Research #News #Trending News

Head and neck cancer
#Head and neck cancer #Oncology #Phase II trial #QBiotics

Phase II data show durable responses in head and neck cancer

QBiotics has announced positive results from its Phase II QB46C-H08 trial, with tigilanol tiglate achieving a 78% Objective Response Rate (ORR) in patients with head and neck solid malignancies who were refractory to standard of care.   The company says the result, based on 14 responses across 18… Read More

#Cancer Research #News

#Cancer vaccine #Head and neck cancer #NEC Corporation #Oncology #Phase I trial #Transgene

100% three-year disease-free survival in head and neck cancer

Transgene and NEC Corporation have reported sustained 100% three-year disease-free survival (DFS) in patients treated with TG4050 in the Phase I part of a randomised Phase I/II trial.   TG4050 is the first individualised neoantigen therapeutic vaccine (INTV) based on the myvac platform.  It is… Read More

#Cancer Research #Editor's Choice #News

T cells
#Collaboration #Evotec #Oncology #Plectonic Biotech #T cell engagers

Partners explore T cell engaging approaches for solid tumours

Evotec and Plectonic Biotech have announced a research collaboration to explore a novel immunotherapy approach for solid tumours.   The collaboration aims to address key challenges that have so far limited the successful application of traditional T cell engager therapies in solid tumours by combining Plectonic’s programmable LOGIBODY… Read More

#Business & Investment #Cancer Research #News

Female researcher in a laboratory
#Oncology #PROTAC #University of Edinburgh

Protein build-up may shape cancer drug response, study finds

The way cancer-causing proteins accumulate in tumours may influence how effectively Proteolysis Targeting Chimeras (PROTAC) drugs can remove them, a new study suggests.   Researchers found that PROTACs were more effective at removing proteins that build up because they are not broken down properly than proteins that cancer… Read More

#Cancer Research #News

Targetted cancer therapy
#Interview #Oncology #Precision medicine #Racura Oncology

Why G‑quadruplex biology is back and what it means for MYC‑driven cancers

Racura Oncology recently raised AU$34.3 (US$24.31) million to fund its RC220 clinical programmes in acute myeloid leukaemia (AML), epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer, and anthracycline cardioprotection in solid tumour patients.  Diana Turner speaks to Dr Peter Smith, Executive Chair of Racura, about… Read More

#Cancer Research #Exclusive Content

CAR-T in multiple myeloma
#CAR-T #Cell therapy #Clinical trial #HaemaLogiX #Oncology

KOALA trial launched to assess CAR-T for myeloma

The first patient has been dosed with PMCC-COE-KMA, an investigational CAR T-cell therapy being developed by Peter MacCallum Cancer Centre’s Centre of Excellence in Cellular Immunotherapy (CoE) and licensed by Australian biotechnology company HaemaLogiX.  The KOALA trial will evaluate the safety and efficacy of PMCC-COE-KMA in patients… Read More

#Cancer Research #News

Colon cancer
#Colorectal cancer #Epigenetics #Juntendo University #Oncology

Study reveals how IL-26 reprogrammes colorectal cancer cells

Researchers have identified inflammatory cytokine interleukin-26 (IL-26) as a factor that acts on cancer cells and induces epigenetic reprogramming, promoting immune evasion.  While cancer cells acquire malignant traits through epigenetic remodelling, it remains unclear how immune-derived inflammatory factors regulate the epigenetics of colorectal cancer cells.  … Read More

#Cancer Research #News #Trending News

CAR-T cells attack cancer cells
#CAR-T #Cell therapy #Oncology #Pancreatic cancer #The University of Texas at Austin

Research uncovers driver of CAR-T resistance in solid tumours

Pancreatic tumours can resist immunotherapy by recruiting nearby immune cells, according to new research, which has revealed a potential new strategy for overcoming resistance in cell therapies.  CAR T-cell therapy has transformed treatment for several blood cancers but has repeatedly stalled against solid tumours such as pancreatic… Read More

#Cancer Research #Editor's Choice #News

#Brain cancer #Chemotherapy #Oncology #The University of Manchester

Glioblastoma therapy timing could be key to treatment

Scientists have identified a brief window after brain tumour surgery during which a treatment for glioblastoma can cross the brain’s protective barrier and reach the cancer cells most likely to trigger tumour regrowth.  The discovery could pave the way for more effective treatments for glioblastoma, the most… Read More

#Cancer Research #Editor's Choice #News